179 related articles for article (PubMed ID: 36848213)
1. Current status and future perspectives of bispecific antibodies in the treatment of lung cancer.
Wang W; Qiu T; Li F; Ren S
Chin Med J (Engl); 2023 Feb; 136(4):379-393. PubMed ID: 36848213
[TBL] [Abstract][Full Text] [Related]
2. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
3. The state of the art of bispecific antibodies for treating human malignancies.
Wang S; Chen K; Lei Q; Ma P; Yuan AQ; Zhao Y; Jiang Y; Fang H; Xing S; Fang Y; Jiang N; Miao H; Zhang M; Sun S; Yu Z; Tao W; Zhu Q; Nie Y; Li N
EMBO Mol Med; 2021 Sep; 13(9):e14291. PubMed ID: 34431224
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies: From Research to Clinical Application.
Ma J; Mo Y; Tang M; Shen J; Qi Y; Zhao W; Huang Y; Xu Y; Qian C
Front Immunol; 2021; 12():626616. PubMed ID: 34025638
[TBL] [Abstract][Full Text] [Related]
5. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
6. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
[TBL] [Abstract][Full Text] [Related]
9. The promise of bispecific antibodies: Clinical applications and challenges.
Lim SM; Pyo KH; Soo RA; Cho BC
Cancer Treat Rev; 2021 Sep; 99():102240. PubMed ID: 34119803
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
11. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
12. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
14. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Caraccio C; Krishna S; Phillips DJ; Schürch CM
Front Immunol; 2020; 11():501. PubMed ID: 32391000
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
[TBL] [Abstract][Full Text] [Related]
18. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic bispecific antibodies against intracellular tumor antigens.
Xu G; Luo Y; Wang H; Wang Y; Liu B; Wei J
Cancer Lett; 2022 Jul; 538():215699. PubMed ID: 35487312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
